Seagen, Inc.
Bothell
WA
United States
865 articles with Seagen, Inc.
-
Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting
3/14/2023
Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023.
-
Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.
-
Pfizer Invests $43 Billion to Battle Cancer
3/13/2023
Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
-
Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
3/9/2023
Astellas Pharma Inc. and Seagen Inc. announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted the Biologics License Application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.
-
Seagen and Pfizer are in early-stage talks over a potential acquisition that could exceed $30 billion.
-
Seagen to Present at the Cowen 43rd Annual Health Care Conference
2/27/2023
Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. Eastern Time.
-
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen
2/17/2023
Daiichi Sankyo Co., Ltd. announced that the U.S. Patent and Trademark Office granted its request to re-institute post-grant review of the patentability of certain claims of Seagen’s U.S. patent 10,808,039.
-
Seagen did not address rumors of a buyout from Merck during its fourth-quarter and full-year financial report. Instead, it focused on upcoming label expansions and its promising pipeline.
-
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
2/15/2023
Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022.
-
Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
2/13/2023
Seagen Inc. (Nasdaq: SGEN) today announced the presentation of new data featuring PADCEV® (enfortumab vedotin-ejfv) at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) taking place from February 16-18, 2023.
-
The FDA granted Seagen's tyrosine kinase inhibitor Tukysa accelerated approval for an aggressive form of colorectal cancer Thursday.
-
Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
1/19/2023
Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to TUKYSA® (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
-
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
1/19/2023
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets.
-
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
-
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
12/20/2022
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV ® (enfortumab vedotin-ejfv) with KEYTRUDA ® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer.
-
Seagen to Present at the J.P. Morgan Healthcare Conference-December 20, 2022
12/20/2022
Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time.
-
Seagen's top-selling drug hit the mark in another major indication.
-
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
12/12/2022
Seagen Inc. (Nasdaq: SGEN) today announced results from two parts of a phase 2 trial (SGN35-027) evaluating ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with classical Hodgkin lymphoma (cHL).
-
Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting
12/1/2022
Seagen to Highlight ADCETRIS ® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting.
-
Seagen’s Adcetris has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma.